Amylin Pharmaceuticals, Inc. today announced positive results from a 28-week dose-ranging study of pramlintide/metreleptin, a combination treatment comprising pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the...

Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved Effient (prasugrel) tablets for the reduction of thrombotic cardiovascular events (including stent thrombosis) in...

The US Food and Drug Administration has approved Valturna (aliskiren and valsartan) tablets, the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS), an important...

As more and more prescriptions are being written for medications to treat attention-deficit hyperactivity disorder (ADHD), more and more children are abusing these drugs.

Men who pack on excess pounds as young adults are at heightened risk of developing prostate cancer, although the risk varies by ethnic group, researchers from the University of Hawaii report.

Investigators Presented Results at the Society of Urologic Oncology Annual Meeting BETHESDA, MD – December 4, 2009 – Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the...

- Roche to Present new Results That Could Offer a Better Future to Women With Early and Very Advanced Breast Cancer, at the CTRC-AACR San Antonio Breast Cancer Symposium   BASEL, Switzerland, Dec. 9 /CNW/ - Roche (SIX: RO, ROG; OTCQX: RHHBY)...

Afamelanotide as an adjunct therapy effective in pilot study of gastro-intestinal cancer treatment Melbourne, Australia 9th December 2009 -- Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that it had obtained...

BERLIN--(BUSINESS WIRE)--Dec 9, 2009 - Knopp Neurosciences Inc. (“Knopp”) announced the presentation today of encouraging clinical results in a Phase 2 safety and tolerability study of KNS-760704 in amyotrophic lateral...

Defibrotide Therapy Demonstrates a Strong Trend Toward Statistical Significance in the Prevention and Treatment of VOD   VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Dec 8, 2009 - Gentium S.p.A. (NASDAQ: GENT) today announced final clinical...